| Literature DB >> 31695976 |
Brittney A Grella1, Mihir Patel1, Satish Tadepalli2, Christopher W Bader1, Kenneth Kronhaus1.
Abstract
Lyme carditis is a rare cardiac manifestation of Lyme disease that occurs when bacterial spirochetes infect the pericardium or myocardium triggering an inflammatory response. The most common electrocardiogram (EKG) findings in these patients include atrioventricular (AV) conduction abnormalities (first, second, and third degree heart block). A 56-year-old male with a history of hypothyroidism, from the Northeastern region of the United States, presented to the emergency department with lightheadedness and chest pain. His EKG revealed sinus bradycardia with a heart rate of 49 beats per minute, without ST segment elevation, T wave inversions, or signs of heart block. An enzyme-linked immunosorbent assay (ELISA) Lyme titer was elevated, and confirmatory Western blot was positive for IgG and negative for IgM. He was treated with intravenous (IV) ceftriaxone; however, he continued to have persistent bradycardia with his heart rate dropping to 20 to 30 beats per minute throughout the night. Additionally, he had several sinus pauses while sleeping, with the longest lasting for 6.1 seconds. A pacemaker and an additional three-week course of IV ceftriaxone was determined to be the best treatment for his resistant bradycardia secondary to Lyme carditis. No symptoms were present at his one month follow-up appointment, as an outpatient, after completing ceftriaxone therapy. The patient follows up with cardiology regularly to have his pacemaker checked. Here we present a unique case of Lyme carditis, without the classical findings of Lyme disease or common EKG findings of AV conduction abnormalities. A high clinical suspicion of Lyme carditis is required when someone from a Lyme endemic region presents with unexplained cardiac symptoms and electrocardiogram abnormalities. This case report aims to add to the knowledge gap between suspicion of Lyme carditis and sinus bradycardia as the only presenting symptom.Entities:
Keywords: bradycardia; lyme carditis; lyme disease; sinus bradycardia
Year: 2019 PMID: 31695976 PMCID: PMC6820318 DOI: 10.7759/cureus.5554
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Patient’s electrocardiogram (EKG) revealing a 1.8 second sinus pause and sinus bradycardia without any atrioventricular (AV) conduction defects.
CDC interpretation and diagnostic criteria for Lyme disease.
CDC - Centers for Disease Control and Prevention.
| CDC Western Blot Criteria | ||
| Positive IgM | 2 of the following 3 bands are present: 24 kDa (OspC) 39 kDa (BmpA) 41 kDa (Fla) | A positive IgM is sufficient to diagnose in early Lyme disease (< 4 weeks of onset of symptoms). |
| Positive IgG | 5 of the following 10 bands are present: 18 kDa 21 kDa (OspC) 28 kDa 30 kDa 39 kDa (BmpA) 41 kDa (Fla) 45 kDa 58 kDa (not GroEL) 66 kDa 93 kDa | At any point in infection, a positive IgG is diagnostic of Lyme disease. |
Antigen specificity in Western blot (Deutsche Borreliose-Gesellschaft e.v., 2010)*.
* Refer [2].
| Borrelia Antigen | Specificity |
| p18 | High |
| p21 | High |
| p22, 23, 24, 25 | High |
| p39 | High |
| p41 | Unspecific |
| p58 | High |
| p66 | Unspecific |
Figure 2CDC's diagnostic criteria for Lyme disease.
CDC - Centers for Disease Control and Prevention.
The suspicious index in Lyme carditis scoring system as proposed by Besant et al.*.
*Refer [11].
| Patient's Characteristics | Score |
| Age < 50 | 1 |
| Male | 1 |
| Outdoor activity/endemic area | 1 |
| Constitutional symptoms (malaise, fever, arthralgias, dyspnea, pre syncope and syncope) | 2 |
| Tick bite | 3 |
| Erythema migrans | 4 |
Antibiotic regimens recommended by the CDC, ILADS, and IDSA for the treatment of Lyme carditis.
CDC - Centers for Disease Control and Prevention; ILADS - International Lyme and Associated Diseases Society; IDSA - Infectious Disease Society of America.
| Lyme Carditis Treatment Regimens | |
| Centers for Disease Control and Prevention (CDC) | |
| Doxycycline 100 mg orally twice daily for 10-21 days or Cefuroxime Axetil 500 mg orally twice daily for 14-21 days or Amoxicillin 500 mg orally three times daily for 14-21 days | |
| International Lyme and Associated Diseases Society (ILADS) | |
| Amoxicillin 1500-2000 mg orally daily in divided doses for 4-6 weeks or Cefuroxime 500 mg orally twice daily for 4-6 weeks or Doxycycline 100 mg orally twice daily for for 4-6 weeks or Azithromycin 250-500 mg orally daily for 21 days | |
| Infectious Disease Society of America (IDSA) | |
| Preferred Treatment | Ceftriaxone 2 grams once per day via IV for 14 days with a range of 10-28 days |
| Alternative Treatments | Cefotaxime 2 grams IV every 8 hours or Penicillin G 18-24 million units per day in patients with normal renal function divided into doses given every 4 hours or Doxycycline 200-400 mg per day in 2 divided doses orally for 10-28 days for patients intolerant of B-lactam antibiotics |
German Borreliosis Society recommendations for the treatment of Lyme disease.
| Antibiotics applicable in Lyme disease (Deutsche Borreliose-Gesellschaft e.v., 2010) [ |
| Beta lactams: Ceftriaxone, Cefotaxime, Cefuroxime Axetil, Benzathine benzylpenicillin, Phenylmethyl Penicillin, Amoxicillin |
| Tetracyclines and glycylcyclines: Doxycycline, Minocycline |
| Macrolides: Clarithromycin, Azithromycin |
| Nitromidazoles: Metronidazole |
| Co-drugs: Hydroxychloroquine |